Medicogen continues to move forward, while being cautious to balance allocation of resources and development risk!
On the licensing front, we think we are nearing finalization of an exclusive deal with Clemson on the key patents. As expected, it has taken some time to align incentives in a way that works for our team and for the university. Stay tuned for updates!
Collaboration with the R&D team has also continued. The goal is to complete in vivo feasibility studies within a year -- the output from this work will dictate the future direction of the company! We are working with the lab to discuss GLP compliance, and considering launching parallel efforts with outside GLP-compliant laboratories, if necessary.
We would welcome questions or feedback from anyone reading this post! Please reach out to CAI or to us directly.